All data are based on the daily closing price as of July 23, 2024
t

TaiMed Biologics

4147.TWO
2.64 USD
-0.01
-0.38%

Overview

Last close
2.64 usd
Market cap
720.25M usd
52 week high
4.30 usd
52 week low
2.34 usd
Target price
2.68 usd

Valuation

P/E
N/A
Forward P/E
1111.1111
Price/Sales
52.182
Price/Book Value
10.0004
Enterprise Value
677.27M usd
EV/Revenue
52.3888
EV/EBITDA
-1046.8754

Key financials

Revenue TTM
18.26M usd
Gross Profit TTM
6.58M usd
EBITDA TTM
486829.27 usd
Earnings per Share
-0.02 usd
Dividend
N/A usd
Total assets
171.88M usd
Net debt
N/A usd

About

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
  • Symbol
    4147.TWO
  • Exchange
    TWO
  • Isin
    TW0004147004
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Chin-Ming Chang Ph.D.
  • Headquarter
    Taipei
  • Web site
    https://www.taimedbiologics.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top